![]() 1 ALI is associated with 30-day amputation and mortality rates as high as 30% and 11.5%, respectively. Common causes include embolization due to cardiac dysrhythmia or thrombus from pre-existing peripheral artery disease. With the clot entrained, the system is withdrawn into a minimum 7 Fr guide sheath through which the clot is removed from the body.ĪLI is characterized by a sudden decrease in arterial perfusion to the limb, with a potential threat to limb survival, requiring urgent evaluation and management. The baskets capture the clot and are retracted into the nitinol collection funnel. The basket wire is delivered distal to the location of the thrombus, deploying two nitinol self-expanding baskets. The Pounce Thrombectomy System is composed of three components: a 5 Fr delivery catheter, a basket wire, and a funnel catheter. We are confident the PROWL registry will demonstrate these exceptional attributes of the Pounce system in real-world clinical practice.” “With hospitals increasingly short on staff and beds, physicians need a simple and effective tool that lets them restore arterial flow right on the table without resorting to time-consuming and costly adjunctive treatments. ![]() “Acute limb ischemia from arteries blocked by thrombus or embolus is an urgent threat to both limb and life,” said Gary Maharaj, President and CEO of Surmodics, Inc. PROWL’s primary efficacy endpoint is procedural success, while the primary safety endpoint is the incidence of device-related major adverse events (MAEs) through 30 days. “In this respect, our experience with the Pounce system has been quite positive.” “We’ve long needed better tools to help us resolve acute limb ischemia in a simple and effective manner, without the use of multiple adjunctive treatments,” he added. We’re eager to help track outcomes in this important study.” “In our experience, the Pounce system promptly removes peripheral arterial clot in a single treatment session while reducing the need for thrombolytic drugs and subsequent ICU stays. Joseph Griffin, Vascular Surgeon, Vascular Specialty Center, LLC and Baton Rouge General Medical Center. “We are delighted to be the first site to enroll a patient in the PROWL registry,” said Dr. The first site to enroll a patient in the registry study was Baton Rouge General Medical Center, Baton Rouge, La. Joseph Campbell, Interventional Cardiologist, OhioHealth, are National Co-Principal Investigators. Sean Lyden, Chairman of the Department of Vascular Surgery, Cleveland Clinic, and Dr. The registry will collect real-world efficacy and safety outcomes data for endovascular interventions using the Pounce system for up to 500 patients at up to 30 sites. registry of the Surmodics Pounce system for the non-surgical removal of emboli and thrombi in the peripheral arterial vasculature. ![]() PROWL is an open-label, retrospective, multi-center, U.S. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced enrollment of the first patient in PROWL, the Pounce™ Thrombectomy System Retrospective Registry.
0 Comments
Leave a Reply. |